Coherus BioSciences Inc. (CHRS) CFO Sells $116,532.00 in Stock
Coherus BioSciences Inc. (NASDAQ:CHRS) CFO Jean-Frederic Viret sold 3,900 shares of the firm’s stock in a transaction dated Monday, September 26th. The shares were sold at an average price of $29.88, for a total transaction of $116,532.00. Following the sale, the chief financial officer now directly owns 6,225 shares in the company, valued at approximately $186,003. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Coherus BioSciences Inc. (NASDAQ:CHRS) opened at 25.45 on Tuesday. The firm’s 50-day moving average is $29.76 and its 200-day moving average is $22.83. Coherus BioSciences Inc. has a 1-year low of $12.04 and a 1-year high of $31.98. The company’s market cap is $1.10 billion.
Coherus BioSciences (NASDAQ:CHRS) last announced its earnings results on Tuesday, August 9th. The company reported ($1.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.32) by $0.40. The firm earned $14.07 million during the quarter, compared to the consensus estimate of $6.87 million. Coherus BioSciences had a negative return on equity of 1,583.92% and a negative net margin of 591.61%. On average, equities analysts forecast that Coherus BioSciences Inc. will post ($6.19) earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the company. Oxford Asset Management purchased a new position in shares of Coherus BioSciences during the second quarter worth approximately $729,000. Columbus Circle Investors increased its position in Coherus BioSciences by 70.3% in the second quarter. Columbus Circle Investors now owns 373,249 shares of the company’s stock valued at $6,304,000 after buying an additional 154,086 shares during the period. Jennison Associates LLC bought a new position in Coherus BioSciences during the second quarter valued at about $228,000. Bridger Management LLC bought a new position in Coherus BioSciences during the first quarter valued at about $7,242,000. Finally, Bellevue Group AG bought a new position in Coherus BioSciences during the first quarter valued at about $6,093,000. Institutional investors and hedge funds own 58.37% of the company’s stock.
A number of analysts have recently issued reports on the stock. Maxim Group assumed coverage on shares of Coherus BioSciences in a report on Wednesday, September 7th. They set a “buy” rating and a $43.00 price target on the stock. Zacks Investment Research downgraded shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a report on Monday, August 15th. Credit Suisse Group AG reissued a “buy” rating and issued a $38.00 price objective on shares of Coherus BioSciences in a report on Wednesday, September 28th. Barclays PLC reissued a “buy” rating and issued a $46.00 price objective on shares of Coherus BioSciences in a report on Thursday, August 11th. Finally, Citigroup Inc. initiated coverage on shares of Coherus BioSciences in a report on Wednesday, July 27th. They issued a “buy” rating and a $36.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $36.50.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.